Drug intelligence / Profile preview

CHP-HER2

Development stage: Phase 1
Modality: Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

CHP-HER2 is a peptide-based cancer vaccine designed to stimulate the immune system against tumor cells expressing the HER-2/neu antigen. The vaccine consists of HER-2-derived peptides formulated with cholesteryl pullulan (CHP) as a delivery system. Vaccination with CHP-HER2 aims to induce both humoral and cytotoxic T-cell responses, leading to inhibition of tumor cell proliferation and direct tumor cell death in cancers that overexpress HER-2/neu, such as certain breast cancers[1]. It is administered subcutaneously and has been studied in combination with immunoadjuvants like OK-432 (Picibanil)[4].

Other names: CHP-HER-2 peptide vaccineCHP-HER2 peptide vaccineCHP-HER 2 peptide vaccine

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CHP-HER2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHP-HER2.

Explore the full profile